These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 35333136)
1. Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein. Das T; Mukhopadhyay C J Biomol Struct Dyn; 2023 May; 41(8):3368-3381. PubMed ID: 35333136 [TBL] [Abstract][Full Text] [Related]
2. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2. Shode FO; Idowu ASK; Uhomoibhi OJ; Sabiu S J Biomol Struct Dyn; 2022 Sep; 40(14):6587-6602. PubMed ID: 33590806 [TBL] [Abstract][Full Text] [Related]
3. Naringenin-4'-glucuronide as a new drug candidate against the COVID-19 Omicron variant: a study based on molecular docking, molecular dynamics, MM/PBSA and MM/GBSA. Cobre AF; Maia Neto M; de Melo EB; Fachi MM; Ferreira LM; Tonin FS; Pontarolo R J Biomol Struct Dyn; 2024 Jul; 42(11):5881-5894. PubMed ID: 37394802 [TBL] [Abstract][Full Text] [Related]
4. Tetracycline as an inhibitor to the SARS-CoV-2. Zhao TY; Patankar NA J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758 [TBL] [Abstract][Full Text] [Related]
5. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. Dehury B; Raina V; Misra N; Suar M J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2. Deepthi V; Mohanakumar KP; Rajamma U J Biomol Struct Dyn; 2023 Apr; 41(7):2911-2925. PubMed ID: 35189779 [TBL] [Abstract][Full Text] [Related]
7. Computational insight of dexamethasone against potential targets of SARS-CoV-2. Fadaka AO; Sibuyi NRS; Madiehe AM; Meyer M J Biomol Struct Dyn; 2022 Feb; 40(2):875-885. PubMed ID: 32924825 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory mechanism of clioquinol and its derivatives at the exopeptidase site of human angiotensin-converting enzyme-2 and receptor binding domain of SARS-CoV-2 viral spike. Kehinde IA; Egbeyemi A; Kaur M; Onyenaka C; Adebusuyi T; Olaleye OA J Biomol Struct Dyn; 2023 Apr; 41(7):2992-3001. PubMed ID: 35220925 [TBL] [Abstract][Full Text] [Related]
9. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies. Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401 [TBL] [Abstract][Full Text] [Related]
10. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070 [TBL] [Abstract][Full Text] [Related]
12. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study. Mishra GP; Bhadane RN; Panigrahi D; Amawi HA; Asbhy CR; Tiwari AK Comput Biol Med; 2021 Jul; 134():104464. PubMed ID: 34020130 [TBL] [Abstract][Full Text] [Related]
13. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An Behera SK; Mahapatra N; Tripathy CS; Pati S Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470 [TBL] [Abstract][Full Text] [Related]
14. Tinocordiside from Balkrishna A; Pokhrel S; Varshney A Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372 [TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. Bagheri M; Niavarani A J Biomol Struct Dyn; 2022 Mar; 40(4):1597-1606. PubMed ID: 33030105 [TBL] [Abstract][Full Text] [Related]
16. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. Basit A; Ali T; Rehman SU J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773 [TBL] [Abstract][Full Text] [Related]
17. Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD. Abu-Saleh AAA; Yadav A; Poirier RA J Biomol Struct Dyn; 2023 Apr; 41(6):2518-2527. PubMed ID: 35132950 [TBL] [Abstract][Full Text] [Related]
18. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods. Ebrahimi M; Karami L; Alijanianzadeh M Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285 [TBL] [Abstract][Full Text] [Related]
19. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984 [TBL] [Abstract][Full Text] [Related]